Last reviewed · How we verify
NCT03450031
Evaluation of Nasal Inflammatory Biomarkers
NA trial testing NAC (no drug/no device) in Seasonal Allergic Rhinitis in 24 participants. Completed in 30 October 2018.
26 April 2018
Quick facts
| Lead sponsor | Fraunhofer-Institute of Toxicology and Experimental Medicine |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 24 |
| Start date | 8 February 2018 |
| Primary completion | 26 April 2018 |
| Estimated completion | 30 October 2018 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- NAC (no drug/no device)
Conditions studied
- Seasonal Allergic Rhinitis — all drugs for Seasonal Allergic Rhinitis →
Sponsor
Fraunhofer-Institute of Toxicology and Experimental Medicine
Who can join
Adults 18 to 65, any sex, with Seasonal Allergic Rhinitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This research aims to establish a panel of inflammatory biomarkers of the early (Histamine, Tryptase, ProstaglandineD2) and late (Interleukin-4, Interleukin-5, Interleukin-6, Interleukin-13, Eotaxin, Tumor necrosis factor-a (TNF), (Macrophage Inflammatory Protein-1beta (MIP1ß)) phase response to nasal bolus allergen challenge (NAC) in subjects with out-of-season seasonal allergic rhinitis, suitable for future application in drug intervention studies of novel anti-allergy therapeutics.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03450031
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Seasonal Allergic Rhinitis
Currently open trials in the same condition.
- NCT07055542 — Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study · NA · recruiting
- NCT06846385 — Phase II/III Seamless Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Treatment of Seasonal Allergic · Phase 2, PHASE3 · recruiting
- NCT07291284 — Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic Rhinitis · Phase 3 · active not recruiting
- NCT06300203 — Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis · Phase 2 · recruiting
- NCT04815668 — Acupuncture at the Sphenopalatine Ganglion in the Treatment of Moderate-to-severe Seasonal Allergic Rhinitis · NA · recruiting
Other Fraunhofer-Institute of Toxicology and Experimental Medicine trials
Trials by the same sponsor.
- NCT06035276 — Biosensor and Environmental Sensor Development Within the REMEDIA Project · NA · completed
- NCT05346718 — Threshold Concentrations for Ragweed and Birch Pollen in Seasonal Allergic Rhinitis · NA · completed
- NCT05245175 — Impact of Carrier Solutions for House Dust Mite Allergen on Allergic Reactions · NA · completed
- NCT05019209 — Skin Responses and T Cell Immunology After House Dust Mite Exposure in Sensitized Atopic Dermatitis Patients · NA · completed
- NCT04914273 — Use of Exhaled Particles to Assess Lung Pharmacokinetics · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03450031 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fraunhofer-Institute of Toxicology and Experimental Medicine
- Last refreshed: 15 February 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03450031.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing